Company profile: Curemark
1.1 - Company Overview
Company description
- Provider of socially-driven biotechnology therapies for neurological diseases, developing CM-AT for Autism Spectrum Disorder (enhancing protein digestion and potentially restoring essential amino acids), CM-4612 (Phase III-ready for ADHD), CM-182 (enzyme replacement therapy for schizophrenia), CM-PK (for Parkinson’s, potentially affecting dopamine), and CM-1212 (for substance use disorders).
Products and services
- CM-4612: Phase III-ready ADHD drug product engineered to benefit children diagnosed with ADHD who are currently on medication
- CM-AT: Orally-delivered autism treatment that enhances protein digestion and may restore essential amino acids in children with Autism Spectrum Disorder
- CM-PK: Drug candidate for Parkinson’s Disease, potentially affecting dopamine levels and improving symptoms like postural instability
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Curemark
Cadent Therapeutics
HQ: United States
Website
- Description: Provider of novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease, leveraging a precision neuroscience approach combining target specificity, patient selection, and drug design and optimization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cadent Therapeutics company profile →
Sage Therapeutics
HQ: United States
Website
- Description: Provider of novel medicines for central nervous system (CNS) disorders, focused on debilitating and disabling conditions. Offers ZURZUVAE, an oral 14-day treatment for adults with postpartum depression, and ZULRESSO, an injectable for patients 15+ with postpartum depression. Pipeline includes SAGE-689 (acute GABA hypofunction), SAGE-421 (NMDA hypofunction), and SAGE-319 (GABA hypofunction).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sage Therapeutics company profile →
Allay Therapeutics
HQ: United States
Website
- Description: Provider of analgesic products for post-surgical pain management and recuperation, including ATX-101, which delivers controlled-release bupivacaine at the surgical site to provide weeks of pain relief after total knee replacement. Offers a proprietary technology platform combining non-opioid analgesics and biopolymers to create dissolvable candidates for localized, extended pain relief.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allay Therapeutics company profile →
Scienture
HQ: United States
Website
- Description: Provider of pharmaceutical research focused on drug screening, with a pipeline including SCN-102 (oral cardiovascular liquid; FDA-accepted NDA), SCN-104 (self-injectable CNS/pain drug-device; advanced development), SCN-107 (long-acting pain injection; formulation optimization with pre-clinical planned), and SCN-106 (early-stage biosimilar; clone selection completed; BIA meeting planned).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scienture company profile →
Acticor Biotech
HQ: France
Website
- Description: Provider of biopharmaceutical development of glenzocimab, a humanized monoclonal antibody fragment targeting platelet GPVI with antithrombotic properties without increasing bleeding risk, for the acute phase of ischemic stroke. Runs clinical trials: ACTISAVE, ACTIMIS, and GREEN in stroke, LIBERATE in myocardial infarction, and GARDEN in SARS-CoV-2-related ARDS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acticor Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Curemark
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Curemark
2.2 - Growth funds investing in similar companies to Curemark
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Curemark
4.2 - Public trading comparable groups for Curemark
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →